R&D Innovation

• HANSIZHUANG

  The phase III clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its primary endpoint of Event-Free Survival (EFS), potentially ushering in a "chemotherapy-free" era in perioperative cancer treatment
• HLX43

  As a potential broad-spectrum anti-tumor PD-L1 antibody drug conjugate (ADC), HLX43 is rapidly advancing as a monotherapy, demonstrating significant advantages of "high efficacy and low toxicity" across multiple therapeutic areas
• FUMAINING

  FUMAINING (luvoxmetinib tablets), an innovative small molecule drug independently developed by Fosun Pharma, received approval for two indications in Chinese mainland, filling the gap in the treatment of rare tumors in China
• FUTUONING

  FUTUONING (fovinaciclib citrate capsules), a CDK4/6 inhibitor, has been launched for two indications, offering a brand-new treatment option for breast cancer patients
• Fosun's second CAR-T product

  The marketing application of Fosun's second CAR-T product, brexucabtagene autoleucel injection, has been accepted by the National Medical Products Administration (NMPA)
• Domestically produced Da Vinci Xi Surgical System

  The Da Vinci surgical system has been successfully localized and commercialized domestically
• Ion Robotic Bronchoscopy

  The Ion Robotic Bronchoscopy (the Ion System) has been successfully approved for launch and commercialization in Chinese mainland